SCHEMBL5583103

SCHEMBL5583103

CN(C)CCNC(=O)Cc1ccc(NC(=O)c2ccc(OCc3ccccc3)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.62
NPC1 O15118 4/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
LTA4H P09960 1/20 0.59
RXFP1 Q9HBX9 2/20 0.59
ALOX5 P09917 2/20 0.59
LMNA P02545 1/20 0.56
EGFR P00533 2/20 0.53
KDM4E B2RXH2 2/20 0.52
POLB P06746 2/20 0.52
HTT P42858 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
NR1H4 Q96RI1 1/20 0.52
MAPT P10636 1/20 0.52
NOX1 Q9Y5S8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5582719 0.95 MEN1 (0.56) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL5582552 0.88 KMT2A (0.59) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL5582695 0.85 TDP1 (0.61) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL14454887 0.85 NR1H4 (0.63) MEN1KMT2AKDM4EPOLBHTT
Hydrochloric Acid SCHEMBL5583003 0.84 NR1H4 (0.62) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL6512669 0.84 ALOX5 (0.55) MEN1KMT2ALTA4HALOX5LMNA
SCHEMBL21568053 0.83 ALOX5 (0.76) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL5582690 0.82 MAPK1 (0.55) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL21568052 0.81 ALOX5 (0.76) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL22192264 0.81 RAB9A (0.94) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US claimed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
EP-1218336-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 2002-07-03 EP disclosed
WO-2001021577-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173498-A1 Melanin concentrating hormone antagonist MC1R, MCHR1, MCHR2 RAB9A 1813/4885NPC1 1085/4885SMN1; SMN2 3652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.